

FORM PTO-390
(REV. 10-2003)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

11245/51003

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

To Be Assigned

10/593804

PRIORITY DATE CLAIMED:

19 March 2004

INTERNATIONAL APPLICATION NO.
PCT/US2005/009583INTERNATIONAL FILING DATE
21 March 2005

TITLE OF INVENTION

HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY

APPLICANT(S) FOR DO/EO/US

LIU and ZHU

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. Preliminary Amendment.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form (one diskette) of the Sequence Listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825, Sequence Listing in paper form (eleven (11) pages) and Sequence Listing Statement.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information: Copy of Published International Application; Sequence Listing in paper form (seven (7) pages) and computer readable form (one (1) diskette); Sequence Listing Statement.

IAP9/Rec'd PCT/PTO 19 SEP 2006

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
To Be Assigned 10/593804	PCT/US2005/009583	11245/51003

a. **THE FILING FEES ARE NOT BEING PAID AT THIS TIME.**

SEND ALL CORRESPONDENCE TO:

KENYON & KENYON

One Broadway

New York, New York 10004

CUSTOMER NO. 26646

FORM PTO-1390 (REV 10-2003)

SIGNATURE

Lawrence P. Casson (Reg. No. 46,606)

NAME

DATE

Page 2 of 2

EXPRESS MAIL NO. EV 321894829 US